美托洛尔联合胺碘酮治疗慢性心力衰竭合并室性心律失常患者的临床研究  

Clinical trial of metoprolol combined with amiodarone in the treatment of patients with chronic heart failure and ventricular arrhythmia

作　　者：张志敏[1] 高淑梅[1] 侯瑞田[1] 李金萍[1] ZHANG Zhi-min;GAO Shu-mei;HOU Rui-tian;LI Jin-ping(Department of Cardioelectrophysiology,Affiliated Hospital of Chengde Medical College,Chengde 067000,Hebei Province,China)

机构地区：[1]承德医学院附属医院心脏电生理科,河北承德067000

出　　处：《中国临床药理学杂志》2020年第10期1180-1182,1190,共4页The Chinese Journal of Clinical Pharmacology

摘　　要：目的观察美托洛尔联合胺碘酮治疗慢性心力衰竭合并室性心律失常患者的疗效及安全性。方法将本院收治的慢性心力衰竭合并室性心律失常患者116例,按随机数字表法分为对照组与试验组,各58例。对照组给予盐酸胺碘酮胶囊,每次0.2 g,每天3次,连续服用1周后改为每天1次;试验组在对照组的基础上联合酒石酸美托洛尔缓释片,每次6.25 mg,每天2次,连续服用1周后改为每次25 mg,维持治疗。2组均连续治疗5个月。治疗后统计2组患者临床疗效及窦性心律维持率,以彩色多普勒超声心动图检测治疗前后心功能指标,比较治疗期间相关药物不良反应发生情况。结果治疗后,对照组与试验组总有效率分别为72.41%,93.10%,差异有统计学意义(P<0.05)。治疗后1,3,6个月,对照组窦性心律维持率分别为58.62%,65.52%,53.45%,试验组分别为75.86%,84.48%,72.41%,差异均有统计学意义(均P<0.05)。治疗后6个月,对照组和试验组左心室射血分数(LVEF)分别为(37.02±6.85)%,(43.17±7.36)%;左心室舒张末期容积(LVEDV)分别为(140.92±32.41),(132.52±21.54)mL;左心室收缩末期容积(LVESV)分别为(75.62±14.96),(67.95±12.37)mL,差异均有统计学意义(均P<0.05)。对照组和试验组的药物不良反应发生率分别为12.06%,8.62%,差异无统计学意义(P>0.05)。结论美托洛尔联合胺碘酮治疗慢性心力衰竭合并室性心律失常可有效改善患者心功能,维持其窦性心律、提高治疗疗效,且安全性良好。Objective To explore the effect and safety of metoprolol combined with amiodarone in the treatment of chronic heart failure with ventricular arrhythmia.Methods A total of 116 chronic heart failure with ventricular arrhythmia patients in our hospital were divided into control group and treatment group according to random number table method,58 cases in each group.Control group were treated with amiodarone hydrochloride capsule 0.2 mg per time,3 times per day,changed to 1 time per day after 1 week continuous use.Treatment group were treated with metoprolol tartrate sustained release tablet(6.25 mg per time,2 times per day,changed to 25 mg per time after 1 week continuous use,maintenance treatment)on the basis of control group.Two groups were treated for 5 consecutive months.The clinical effect and sinus arrhythmia maintenance rates of patients in two groups after treatment were statisticsed,the cardiac function indexes before and after treatment were detected by color doppler echocardiography,the related adverse drug reactions occurrence during treatment were compared.Results The total clinical effective rates in control group and treatment group after treatment were 72.41%,93.10%,with significant difference(P<0.05).The sinus arrhythmia maintenance rates at 1,3,6 months after treatment in control group were58.62%,65.52%,53.45%,and were 75.86%,84.48%,72.41%in treatment group,all with significant difference(all P<0.05).At 6 months after treatment,the left ventricular ejection fraction(LVEF)in control group and treatment group were(37.02±6.85)%,(43.17±7.36)%;the left ventricular end-diastolic volume(LVEDV)were(140.92±32.41),(132.52±21.54)m L;left ventricular end systolic volume(LVESV)were(75.62±14.96),(67.95±12.37)m L,all with significant difference(all P<0.05).The incidence of adverse drug reactions in control group and treatment group were 12.06%,8.62%,with no significant difference(P>0.05).Conclusion Metoprolol combined amiodarone can effectively improve the cardiac function of chronic heart failure with vent

关 键 词：慢性心力衰竭 室性心律失常 胺碘酮 美托洛尔 心功能 

分 类 号：R972[医药卫生—药品]